{
    "clinical_study": {
        "@rank": "168073", 
        "arm_group": {
            "arm_group_label": "Hemospray Group", 
            "arm_group_type": "Experimental", 
            "description": "Hemospray device consists of a syringe containing the Hemospray powder (21 g per syringe), a delivery catheter that will be inserted into the working channel of the endoscope, and an introducer handle with a built-in carbon dioxide canister to propel the Hemospray powder out of the catheter.\nIn addition to Hemospray device any other required endoscopic accessories can be used during the procedure."
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the effectiveness of Hemospray in achieving initial\n      hemostasis and decreased rate of re-bleeding in patients of acute variceal bleeding."
        }, 
        "brief_title": "Clinical Evaluation of Hemospray in Hemostasis of Active Variceal Bleeding", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Variceal Hemorrhage", 
        "condition_browse": {
            "mesh_term": "Hemorrhage"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  18 Years and older\n\n          -  Bleeding Esophageal and / or Gastric varices\n\n        Exclusion Criteria:\n\n          -  Patient is: < 18 years of age\n\n          -  Unable to consent\n\n          -  Contraindicated to undergo endoscopy,\n\n          -  Already hospitalized for another illness\n\n          -  Pregnant or lactating\n\n          -  Patients with altered post-surgical anatomy of the stomach\n\n          -  Previously placed intrahepatic portosystemic shunt\n\n          -  Patient treated by other endoscopic or surgical modalities within 7 days prior to the\n             intended application of Hemospray"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01783899", 
            "org_study_id": "Hemospray Varices"
        }, 
        "intervention": {
            "arm_group_label": "Hemospray Group", 
            "description": "Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.\nonce the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.\nHemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.\nOnce bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.\nOral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.\nRecurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care", 
            "intervention_name": "Hemospray", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": "Hemostatics"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 4, 2013", 
        "location": [
            {
                "contact": {
                    "email": "jacques.deviere@erasme.ulb.ac.be", 
                    "last_name": "Jacques , Deviere", 
                    "phone": "003225553712"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1070"
                    }, 
                    "name": "Erasme Hospital , ULB"
                }, 
                "investigator": [
                    {
                        "last_name": "Jacques Deviere, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Mostafa Ibrahim, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ibrahimmostafa@egyptgastrohep.com", 
                    "last_name": "Ibrahim Mostafa, PhD", 
                    "phone": "00201222113466"
                }, 
                "facility": {
                    "address": {
                        "city": "Giza", 
                        "country": "Egypt", 
                        "zip": "12311"
                    }, 
                    "name": "Theodor Bilharz Research Institute"
                }, 
                "investigator": [
                    {
                        "last_name": "Ibrahim Mostafa, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ahmed El Mikkawy, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Mostafa Ibrahim, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Egypt"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Evaluation of Hemospray in Hemostasis of Active Variceal Bleeding", 
        "overall_contact": {
            "email": "mostafa.ibrahim@me.com", 
            "last_name": "Mostafa Ibrahim, MD", 
            "phone": "00201006107100"
        }, 
        "overall_official": {
            "affiliation": "Universit\u00e9 Libre de Bruxelles", 
            "last_name": "Mostafa Ibrahim, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety will be characterized by the incidence of all Adverse Device Effects (ADEs), non-serious and serious, possibly related to or related to the procedure and/or device that are experienced by study participants.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01783899"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Theodor Bilharz Research Institute", 
            "investigator_full_name": "Mostafa Ibrahim", 
            "investigator_title": "Gastroenterologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Information on efficacy will be obtained by measurements the proportion of patients with acute (procedural) hemostasis, and the rate of recurrent bleeding within 72 hours of treatment.", 
            "measure": "Effectiveness", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "source": "Theodor Bilharz Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Universit\u00e9 Libre de Bruxelles", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Theodor Bilharz Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}